Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169353 | 1.00 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29463791 | 0.98 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4008149 | 0.98 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4013722 | 0.98 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL10651872 | 0.93 | SLC18A3 (0.44) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL7471598 | 0.90 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL3921393 | 0.89 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL3923917 | 0.89 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL29889405 | 0.89 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL14868820 | 0.89 | SLC18A3 (0.42) | SLC18A3SIGMAR1HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SLC18A3 267/4885SIGMAR1 229/4885HTR1A 136/4885 |
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | SLC18A3 3178/4885SIGMAR1 3943/4885HTR1A 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.